Skip to main content

Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”

A Letter to the Editor to this article was published on 27 August 2019

The Original Article was published on 04 April 2019

This is a preview of subscription content, access via your institution.


  1. Concordet D, Gandia P, Montastruc J-L, Bousquet-Mélou A, Lees P, Ferran A, et al. Levothyrox new and old formulations: are they switchable for millions of patients? Clin Pharmacokinet. 2019;58(7):827–33. 4 Apr 2019).

    Article  PubMed  PubMed Central  Google Scholar 

  2. FDA Guidance document “Statistical Approaches to Establishing Bioequivalence”. 2001. Accessed 20 June 2019.

  3. ANSM Levothyrox public report. Accessed 20 June 2019.

  4. ANSM: Contrôle de la nouvelle formule de Lévothyrox commercialisée à partir de mars 2017: note de synthèse 17-A-12th September 2017. file:///C:/Users/502264/Downloads/Rapport%20danalyse%20Agence%20(CTROL)%20_%20Levothyrox.pdf.

  5. Pharmacovigilance report: third report 6/7/2018 Comité technique de pharmacovigilance du 06/07/2018. Accessed 20 June 2019.

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Philippe Lechat.

Ethics declarations


No external funding was used in the preparation of this letter.

Conflict of interest

Philippe Lechat, Jacques Ropers, Jérome Barré, and Stephane Mouly declare that they have no potential conflicts of interest that might be relevant to the contents of this letter.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Lechat, P., Ropers, J., Barré, J. et al. Comment on: “Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?”. Clin Pharmacokinet 58, 1351–1352 (2019).

Download citation

  • Published:

  • Issue Date:

  • DOI: